A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.

Shiraj Sen,Meredith Ann McKean,Laura Sierra,Jessica Ainscough,Jay Yang,Anthony Hamlett,Tom Zimmerman,Melinda S. Merchant,Sant P. Chawla

A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.

2020

Shiraj Sen
Meredith Ann McKean
Laura Sierra
Jessica Ainscough
Jay Yang
Anthony Hamlett
Tom Zimmerman
Melinda S. Merchant
Sant P. Chawla

TPS11573Background: Epithelioid sarcoma (ES) is characterized by loss of inhibitor of integrase 1 (INI1), allowing enhancer of zeste homologue 2 (EZH2) to repress cell differentiation and promote t...

Keywords:

double blind
Placebo-controlled study
Doxorubicin
Internal medicine
Gastroenterology
Tazemetostat
Pathology
Medicine
Epithelioid sarcoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations